#handover
NTrans Technologies BV is moving towards a new phase, and this means that as of this week I am handing over my tasks and responsibilities as acting CEO.
My gratitude goes out to NTrans Technologies BV (former) colleagues, investors and colla…https://t.co/5Co05i8qgw
Gen-therapie tegen ziekte van #Duchenne
Hoe een biotechbedrijf en het LUMC elkaar aantrekken. In het LUMC is Annemieke Aartsma-Rus een van de wetenschappers die strijden tegen deze ellendige ziekte.
@NtransTech @oligogirl @LUMC_Leiden
Het Leidsch Dagblad besteedt aandacht aan het bruisende Leiden Bio Science Park.
Erg leuk om NTrans Technologies BV te mogen presenteren:
Ons werk is alleen mogelijk met een sterk team (Liedeke van Uden, Sebastiaan Kuiper, Marie…https://t.co/2qpBt8iCL9 https://t.co/1A6YpgnIfA
We were extremly happy to meet with @LabTajbakhsh@GraziellaMessi1@Niels_Geijsen and @SOPcMarco from @NtransTech to discuss new insights and pool our ressources in favor of therapies for NMD, in the warm-welcoming Chateau du Mée 🏰 MuscleDare...Just be aware!
RESEARCH TECHNICIAN
NTrans Technologies
Leiden location, The Netherlands
Nov 1st, 2021
Join us in developing breakthrough therapies for genetic disorders.…https://t.co/3yHAT5Hidp
Our partner NTrans Technologies in Utrecht/ Leiden is recruting for a project on gene editing therapies
- a research scientist
- a research technician
@NtransTech@SOPcMarco
https://t.co/7kYbBL912Y
Many thanks to the @ntrans team, the EU_#horizon2020 and @CORDIS_EU teams for completing our H2020 project in these challenging times!
Stay safe and healthy ! https://t.co/6MuO68UTbD
In this video, our advisor, Jennifer Doudna, explains how #CRISPR works and how it can be used for genetic disease treatments. @TEDTalks@doudna_lab https://t.co/XPe15Hm01o
Proud to announce our first joint meeting with @HollandBIO! Scientists and leading industry professionals will address the emerging trends and challenges in the field of cell and gene therapies. Register here:
https://t.co/N8OoD0j77R.
On Okt 15, Prof. Dr. N. Geijsen and Prof. Dr. J. van der Oost contribute to
https://t.co/PIkGh65USA
"....various scientists will give an overview of the CRISPR/Cas technology, the fantastic possibilities that the technology provides, but also discuss the potential risks".
We are looking for an Early Stage Researchers to join our team at MIMETAS and develop 3D in vitro models of the neurovascular unit in an international H2020 collaboration.
Learn more here: https://t.co/H5xVEGQGH0
#organonachip#science#research#biotech#sciencejob